A new trading day began on Friday, with Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) stock price up 7.10% from the previous day of trading, before settling in for the closing price of $0.27. ADAP’s price has ranged from $0.20 to $1.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 175.28%. Meanwhile, its annual earnings per share averaged -74.52%. With a float of $228.63 million, this company’s outstanding shares have now reached $257.85 million.
Considering the fact that the conglomerate employs 506 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 98.06%, operating margin of -36.31%, and the pretax margin is -38.17%.
Adaptimmune Therapeutics Plc ADR (ADAP) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.33%, while institutional ownership is 34.06%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -74.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.83% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Here are Adaptimmune Therapeutics Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Compared to the last year’s volume of 1.58 million, its volume of 0.44 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 48.63%. Additionally, its Average True Range was 0.03.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 19.88%, which indicates a significant decrease from 57.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.48% in the past 14 days, which was lower than the 116.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2651, while its 200-day Moving Average is $0.6312. Nevertheless, the first resistance level for the watch stands at $0.3049 in the near term. At $0.3172, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3420. If the price goes on to break the first support level at $0.2678, it is likely to go to the next support level at $0.2430. Now, if the price goes above the second support level, the third support stands at $0.2307.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
With a market capitalization of 75.42 million, the company has a total of 265,052K Shares Outstanding. Currently, annual sales are 178,030 K while annual income is -70,810 K. The company’s previous quarter sales were 7,290 K while its latest quarter income was -47,580 K.
